DEFA14A: Anteris Postpones Shareholder Meeting Due to Lack of Quorum

Anteris Technologies Global Corp. adjourned its Special Meeting of Stockholders to September 29, 2025, after failing to achieve a quorum for key proposals, including an ASX waiver for issuing new securities.

Summary

• Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) adjourned its Special Meeting of Stockholders, originally convened on September 18, 2025, due to a lack of the required quorum.
• The adjourned Special Meeting will now be held virtually on Monday, September 29, 2025, at 8:00 a.m. Central time.
• The primary purpose of the meeting is to approve an ASX waiver from Listing Rule 7.1, which would permit the company to issue new securities without obtaining stockholder approval.
• The record date for the Special Meeting, August 11, 2025, remains unchanged.
• The Board of Directors unanimously recommends voting FOR the proposals.

Sentiment

Score: 4

Explanation: The adjournment due to lack of quorum is a negative procedural event, indicating a lack of immediate shareholder engagement. However, the company has promptly rescheduled and reiterated the board's unanimous recommendation, mitigating some of the negative impact. The underlying proposals, particularly the ASX waiver, could be positive for future flexibility if approved.

Positives

• The company is actively working to ensure stockholder participation by rescheduling the meeting and extending voting deadlines.
• The Board of Directors unanimously recommends voting FOR the proposals, indicating internal alignment on the strategic direction.

Negatives

• The initial Special Meeting was adjourned due to a lack of the required quorum, indicating insufficient stockholder engagement or participation.
• The adjournment introduces a delay in approving key proposals, specifically the ASX Waiver Proposal, which could impact future strategic flexibility.

Risks

• Uncertainties related to achieving a quorum at the adjourned Special Meeting.
• Uncertainties regarding the receipt of stockholder approval for the proposals presented at the Special Meeting, particularly the ASX Waiver Proposal.
• General risks described under "Risk Factors" in Anteris' Annual Report on Form 10-K filed on March 12, 2025 (as amended April 29, 2025) and Quarterly Reports on Form 10-Q filed on May 13, 2025, and August 11, 2025.

Future Outlook

The company's forward-looking statements acknowledge uncertainties regarding the achievement of a quorum at the rescheduled Special Meeting and the ultimate approval of the proposed resolutions by stockholders.

Management Comments

• The Company's Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company's Proxy Statement.

Industry Context

This filing is primarily procedural and governance-related, focusing on stockholder voting and an ASX waiver. It does not directly relate to broader industry trends or competitors, other than Anteris' general business as a structural heart company developing medical devices like the DurAVR THV. The approval of the ASX waiver could provide the company with greater flexibility in capital management, which is a common strategic consideration for growth-oriented medical device companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Required to re-engage or confirm their votes for the rescheduled meeting. The outcome of the ASX Waiver Proposal could impact their dilution risk or the company's ability to raise capital efficiently in the future.
• Management/Board: Must ensure sufficient quorum and votes are secured for the rescheduled meeting to avoid further delays and demonstrate effective governance.
• Regulatory Bodies (ASX/SEC): The company is adhering to regulatory requirements by disclosing the adjournment and rescheduling. The ASX waiver itself is a matter of regulatory compliance and flexibility.

Next Steps

• Stockholders are urged to vote their shares or CDIs before the new deadlines (September 25, 26, or 28, 2025, depending on method).
• The adjourned Special Meeting will be held virtually on September 29, 2025.
• Stockholders are encouraged to read the definitive Proxy Statement filed on August 18, 2025, and any other relevant SEC filings.

Key Dates

Recommendation

The adjournment of the Special Meeting due to a lack of quorum is a procedural setback, indicating potential challenges in shareholder engagement. However, the company has promptly rescheduled the meeting and reiterated the board's unanimous recommendation for the proposals, including the ASX waiver which could offer future capital flexibility. While the delay is a negative, it's not indicative of fundamental operational issues. Investors should hold to see the outcome of the rescheduled meeting and the approval of the ASX waiver, which could be a positive for long-term strategic options.

Keywords

Anteris Technologies, AVR, ASX Waiver, Shareholder Meeting, Proxy Statement, Corporate Governance, Quorum, SEC Filing, Medical Devices, Structural Heart, DurAVR, ADAPT tissue